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Previews‘‘only partially.’’ The RIPK knockout
mutant shows a reproducible reduction
in RIN4 phosphorylation in response to
AvrB, but no reduction in response to
AvrRpm1, as assessed with an anti-phos-
pho-T166 antibody. Consistent with this
result, growth of a P. syringae strain ex-
pressing AvrB is only slightly enhanced
in the ripK knockout, and the number of
cells undergoing RPM1-induced cell
death in response to this strain is slightly
reduced. The authors speculate that the
likely reason for these relatively modest
effects is functional redundancy with
other RLCK family members. Unfortu-
nately, the large number of similar family
members precludes an easy test of this
hypothesis.
Another puzzling result is that AvrB and
RIPK appear to compete for the same
binding site on RIN4; when all three
proteins are coexpressed, only AvrB
immunoprecipitates with RIN4. It thus
remains a possibility that AvrB phosphor-
ylates RIN4 directly. Since the authors
also show that RIPK can phosphorylateAvrB, one plausible model is that RIPK
functions to phosphorylate AvrB, which
then activates AvrB kinase activity
(Figure 1B). The reduced phosphorylation
of RIN4 in the ripK mutant background
would then be the result of reduced AvrB
activation.
Regardless of which model ultimately
proves correct, the work of Chung et al.
and Liu et al. have clearly established
that NLR proteins can be activated by
phosphorylation of other associated host
proteins. It will be of interest to see how
widespread this mechanism is among
other plant and animal NLRs. At a more
mechanistic level, the interesting question
now becomes how phosphorylation of
RIN4 alters its interaction with RPM1,
and how this change leads to activation
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Nasopharyngeal colonization by Streptococcus pneumoniae precedes invasive disease and mediates
community transmission of the pathogen. In this issue,Moffitt et al. (2011) used proteomic analysis to identify
conserved pneumococcal protein vaccine antigens that elicit TH17-dependent responses capable of
preventing such colonization.Streptococcus pneumoniae (the pneu-
mococcus) is one of the foremost bacte-
rial pathogens in humans, causing
massive global morbidity and more than
a million deaths each year. However, it
is essentially a commensal organism,
asymptomatically colonizing the naso-
pharynx of a significant proportion of
the human population, particularly young
children and the elderly. Such carriage
acts as a reservoir for transmission ofthe organism in the community, as well
as a beachhead for subsequent penetra-
tion to otherwise sterile sites, including
the middle ear cavity, lungs, blood,
and brain, resulting in pneumococcal
disease.
Development of effective and afford-
able pneumococcal vaccines has been
a global health priority for many decades.
Vaccines comprising purified capsular
polysaccharides, the dominant pneumo-coccal surface antigens, were licensed
in the late 1970s. However, these suffered
from the shortcoming of poor immunoge-
nicity in high-risk groups (particularly
young children) because the component
polysaccharides are T cell-independent
antigens. Furthermore, the vaccine for-
mulations (initially 14- and later 23-valent)
provided incomplete coverage of the
more than 90 known capsular serotypes
of S. pneumoniae., February 17, 2011 ª2011 Elsevier Inc. 89
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PreviewsThe poor immunogenicity of the poly-
saccharide antigens has been overcome
by conjugation to protein carriers to elicit
boostable, T cell-dependent immune re-
sponses. These conjugate vaccines are
highly immunogenic in infants, and a
7-valent formulation covering the most
important pediatric serotypes was first
licensed in the late 1990s; it has since
been incorporated into the routine child-
hood immunization programs in a number
of countries. This vaccine has been
spectacularly successful in reducing the
incidence of invasive pneumococcal
disease due to included serotypes in the
target population. Moreover, the vaccine
resulted in a massive reduction in asymp-
tomatic nasopharyngeal carriage of these
serotypes and a concomitant significant
‘‘herd immunity’’ effect in nonvaccinees
(Centers for Disease Control, 2005).
However, overall efficacy has been limited
by the fact that the geographic distri-
bution of disease-causing serotypes of
S. pneumoniae is not uniform, nor is it
static. The 7-valent vaccine was formu-
lated with reference to the commonest
pediatric serotypes in North America
(covering 85%–90% of invasive infec-
tions), but coverage is significantly lower
in other important geographic regions,
includingpopulationswith ahighpneumo-
coccal disease burden. Superimposed on
this are temporal changes in serotype
prevalence induced by the vaccine itself.
The high anticapsular antibody levels
elicited by the vaccine are capable of
blocking establishment of nasopharyn-
geal colonization by a vaccine-type pneu-
mococcus. However, the vacated niche is
being increasingly occupied by nonvac-
cine type pneumococci (so-called re-
placement carriage). Serotype replace-
ment in the nasopharynx inevitably leads
to serotype replacement in pneumo-
coccal disease, as has been observed in
a number of studies (Hicks et al., 2007).
The impact of widespread use of conju-
gate vaccines on the complex biology of
pneumococcal disease is difficult to
predict. The full effect of the vaccine on
serotype prevalence may take many
years to become apparent and will vary
from region to region depending upon
levels of endemic carriage, baseline sero-
prevalence, and rates of vaccine utiliza-
tion. Reformulation of conjugate vaccines
to account for geographic differences
and vaccine-driven changes in serotype90 Cell Host & Microbe 9, February 17, 2011prevalence may be necessary (10- and
13-valent formulations have recently
been licensed), but there are cost implica-
tions, as well as a limit to the number
of serotypes that could ever be
accommodated.
In this issue of Cell Host & Microbe,
Moffitt et al. (2011) describe a major step
toward development of a vaccine that
prevents colonization by all pneumococci
regardless of serotype, bypassing the
serotype replacement issue altogether.
This study was built on earlier work from
their laboratory aimed at understanding
the mechanism whereby humans develop
age-related natural resistance to pneumo-
coccal carriage, a process that did not
correlate with acquisition of anticapsular
antibodies (Lipsitch et al., 2005). They
subsequently demonstrated that mucosal
immunization of mice with killed, nonen-
capsulated pneumococci or a mixture of
purified protein antigens protected them
from colonization with S. pneumoniae in
an antibody-independent fashion (Malley
et al., 2005; Basset et al., 2007); this
protective effect was dependent on inter-
leukin (IL)-17A-producing CD4+ T cells
(TH17 cells) (Lu et al., 2008). Immunization
did not prevent establishment of coloniza-
tion like the conjugate vaccine but rather it
promoted clearance of colonizing pneu-
mococci by recruitment of neutrophils to
the nasopharyngeal mucosa.
Moffitt et al. (2011) have now screened
an E. coli expression library (comprising
over 2000 clones) representing >96% of
the proteins encoded by the pneumo-
coccal genome for antigens that elicit
the strongest TH17 responses. This in-
volved pulsing murine peritoneal macro-
phages with pools of clones, followed by
incubation with CD4+ T cells harvested
from mice that had been immunized with
their whole-cell vaccine. Culture superna-
tants were subsequently assayed for
IL-17A to identify those antigen pools
that activated TH17 cells. Clones from
positive pools were then tested individu-
ally. The amino acid sequences of the
proteins expressed by each of the 100
positive clones were then subjected to
bioinformatic analysis to prioritize candi-
date antigens (those >100 aa in length
with >90% identity in all of the 22
sequenced S. pneumoniae genomes,
without homology to any human proteins,
and with <40% identity to other bacterial
proteins).ª2011 Elsevier Inc.Five of the seventeen antigens that
passed this screen were then selected
on the basis of high expression in recom-
binant E. coli and successfully purified.
Two of these, SP0148 and SP2108 (the
solute-binding components of ABC trans-
port systems specific for aromatic amino
acids and maltose, respectively), induced
IL-17A secretion when used to stimulate
splenocytes from three different mouse
strains that had been infected intranasally
with live S. pneumoniae. Furthermore,
separate stimulation of peripheral blood
mononuclear cells from several healthy
human donors with the same two anti-
gens also resulted in IL-17A secretion,
indicating that antigen-specific TH17 cells
are primed during natural exposure of hu-
mans to pneumococci. Thus, in humans
and mice, the antigens are accessible to
antigen-presenting cells during mucosal
colonization and processed for presenta-
tion to CD4+ T cells. Finally, Moffitt et al.
(2011) demonstrated that mucosal immu-
nization with either SP0148 or SP2108
conferred highly significant protection
against colonization with S. pneumoniae
in two separate strains of mice. Protection
required both CD4+ T cells and IL-17A,
as treatment of immunized mice with
anti-CD4 or anti-IL-17A before and after
challenge abrogated protection. Other
proteins identified in the screen that eli-
cited slightly weaker IL-17A responses
than SP0148 or SP2108 did not confer
significant protection against coloniza-
tion, nor did mucosal immunization with
StkP, another pneumococcal surface pro-
tein known to elicit antibody-dependent
protection against invasive disease after
parenteral immunization.
The findings of Moffitt et al. (2011) are
significant for several reasons. First, they
show that it may be possible to almost
completely prevent nasopharyngeal car-
riage of all pneumococci, regardless of
serotype, by mucosal immunization with
just a handful of purified protein antigens.
Such a vaccine could have a major and
sustained impact on global morbidity
and mortality from invasive pneumo-
coccal disease, as colonization almost
invariably precedes invasive disease.
Moreover, because asymptomatic car-
riers are the major reservoir for transmis-
sion of pneumococci in the community,
a substantial herd immunity effect would
be predicted. A potential caveat, how-
ever, is whether complete eviction of
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ties for other potential pathogens that nor-
mally compete with the pneumococcus
for the nasopharyngeal niche. A second
significant finding is that although many
studies have demonstrated that paren-
teral immunization with other conserved
pneumococcal proteins can elicit anti-
body-dependent protection against inva-
sive disease (summarized by Paton,
2011), these proteins were not among
those identified in the TH17 screen. This
indicates substantial nonoverlap between
sets of antigens recognized by protective
antibodies and TH17 cells. Third, the
screening approach described by Moffitt
et al. (2011) is directly applicable to
identification of potentially protective
TH17-dependent antigens displayed by
other mucosal pathogens, such as non-
typable Haemophilus influenzae, Neisseria
meningitidis, Staphylococcus aureus,
Bordetella pertussis, and Mycobacterium
tuberculosis.
In the above studies, TH17-dependent
protection against pneumococcal coloni-
zation elicited by mucosal immunization
required coadministration with cholera
toxin, a strongmucosal adjuvant. Although
nontoxic mucosal adjuvants are available,there are still regulatory hurdles to be
overcome as far as human use is con-
cerned. In this context, a recent study
has shown that subcutaneous immuniza-
tion with whole-cell vaccine, using an
aluminum hydroxide adjuvant formulation
approved for human use, also elicited
strongTH17-dependentprotectionagainst
pneumococcal colonization. Significantly,
however, it also elicited antibody-depen-
dent protection against fatal sepsis (Lu
et al., 2010). This raises the prospect of a
single, injectable alum-adjuvanted vac-
cine formulation combining the purified
proteins that elicit thebest TH17 responses
to prevent carriage (i.e., SP0148 and
SP2108) with other pneumococcal pro-
teins, such as pneumolysin, CbpA, and
PspA, known to elicit strong antibody-
dependent protection against invasive
disease (Ogunniyi et al., 2007). Such
a vaccine would provide two distinct lines
of defense against this formidable
pathogen.REFERENCES
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